Conference Coverage

MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer

Publish date: September 19, 2017

 

AT ESMO 2017

Pages

Recommended Reading

LIFSCREEN data support broader cancer screening in Li-Fraumeni syndrome
MDedge Hematology and Oncology
Annual mammograms from age 40 linked with greatest reductions in mortality
MDedge Hematology and Oncology
FDA expands approval of fulvestrant for HR+/HER2– advanced breast cancer
MDedge Hematology and Oncology
Focus on lifestyle to manage menopause symptoms after breast cancer
MDedge Hematology and Oncology
Assessing a multidisciplinary survivorship program in a group of predominantly Hispanic women with breast cancer
MDedge Hematology and Oncology
An ASCO 2017 recap: significant advances continue
MDedge Hematology and Oncology
Ribociclib: another CDK inhibitor hits the mark in breast cancer
MDedge Hematology and Oncology
Ten-year outcomes support skipping axillary lymph node dissection with positive sentinel nodes
MDedge Hematology and Oncology
Surgeons strongly influenced chances of contralateral prophylactic mastectomy
MDedge Hematology and Oncology
LORELEI sings praises of neoadjuvant taselisib/letrozole in ER+/HER2– breast cancer
MDedge Hematology and Oncology